Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
The results of the Unicancer and the Canadian Cancer Trials Group (CCTG) PRODIGE 24 | CCTG PA.6 study have been published in the New England Journal of Medicine. The practice changing results indicate a significant improvement in the survival of pancreatic cancer patients treated with the mFOLFIRINOX chemotherapy compared to the current standard treatment with gemcitabine
Congratulations to Professor Janette Vardy (University of Sydney) and Doctor Haryana Dhillon (University of Sydney) who were successful in their funding application to the National Health and Medical Research Council (NHMRC) to continue the CCTG led CHALLENGE (CO.21) trial in Australia
As we embark on a new year, it is time to reflect on what we have accomplished together this year and what 2019 will bring. It has been a busy year with continued growth and expansion across our national and international networks.
Congratulations to the researchers who presented abstracts at the American Society of Hematology Annual Meeting (ASH) and San Antonio Breast Cancer Symposium.
The Commonwealth Neuroendocrine Tumour (CommNETs) Research Collaborative hosted a Clinical Trial Workshop in Hong Kong December 8-9th 2018. Formed in 2015, CommNETs operates within the auspices of the Canadian Cancer Trials Group and the Australasian Gastro-intestinal Trials Group to bring together researchers, clinicians, and consumers from Australia, New Zealand and Canada to improve the outcomes of patients with Neuroendocrine Tumours (NETs).
The Pharmacist Network is actively seeking volunteers as Pharmacist Representatives for the Breast and Gastrointestinal Disease Site Committees. Participation in these opportunities earns volunteers a fully funded invitation to the annual CCTG Spring Meeting in Toronto.
The Pharmacist Disease Site Committee representative is expected to represent the perspective of the Pharmacist community during discussion of potential new studies and ongoing trials. Please review terms of reference at:
When it comes to cancer, a lot can happen in 30 minutes. Someone can have a life-changing appointment with their doctor, receive a supportive phone call from a peer or start cancer treatment.
